location
Oakland, California
investment range
$5.0m - $12.0m
sweet spot
$7.0m
most interested in
Enterprise healthcare IT, digital health, healthcare services, medical technologynot interested in
We don't deploy capital in: (1) new molecule development, (2) outside of the US, (3) in businesses that compete directly with Kaiser Permanente (Medicare Advantage plans, for example).Daniel van den Bergh's Past Investments (10)
| Company | Deal Type | Amount | Date | |
|---|---|---|---|---|
| Nuvolo | Series B | $12M (Lead) | Jul 2019 | |
| NextHealth Technologies | Series B | $20M | Mar 2019 | |
| Collective Medical Technologies | Series A | $47.5M | Nov 2017 | |
| Protenus | Series A | $7M (Lead) | Jul 2017 | |
| QuantiaMD | Series E | $12M (Lead) | Aug 2013 | |
| Sotera Wireless | Series D1 | $15M (Lead) | May 2013 | |
| Prognos | Series B | $15M | May 2013 | |
| NuPathe | PIPE | $28M | Oct 2012 | |
| Putney Vet | Series C | $21M (Lead) | Sep 2011 | |
| Advanced Biohealing | Acquisition | $750M | May 2011 |
Daniel van den Bergh's Education
The Wharton School MBA Healthcare and entrepreneurship
Cornell University BS Biological Engineering
Daniel van den Bergh's Media
No media found for Daniel van den Bergh.
Find Daniel van den Bergh on
cb